ʻO Future Market Insights (FMI), i kāna hōʻike, hoʻolālā i ka honua ka hoʻokuʻu waha ʻana i ka mākeke ʻenehana lawe lāʻau e hoʻopaʻa inoa i kahi hoʻonui kupaianaha ma 7.2% CAGR i ka wā wānana 2017 a i 2027. E ʻoi aku ka mākeke i nā loaʻa kālā he US $ 20,000 Mn ma 2017, a ua manaʻo hou ʻia a hiki i kahi kokoke i US $ 50,000 Mn e 2027-hopena.
Hiki i nā mea hana o ka waha ma ʻAmelika ʻĀkau ke loaʻa i ka bioavailability nui
Manaʻo ka hōʻike a FMI i ʻAmelika ʻĀkau e noho mau i ka mākeke nui loa no ka ʻenehana hoʻokuʻu ʻana i ka lāʻau lapaʻau, me ke kūʻai ʻana i manaʻo ʻia e hōʻea ma kahi o US $ 20,000 Mn e 2027-hopena. ʻO ke ala ʻoi loa o ka hoʻokele lāʻau lapaʻau e nā kauka, koi ʻia ka noi no ka hoʻokuʻu ʻana i ka ʻenehana lawe lāʻau lapaʻau e ʻike i ka piʻi ʻana e nā mea hoʻohana hope ma ʻAmelika ʻAmelika. Eia kekahi, ʻo nā holomua hou i ka hāʻawi ʻana i ka lāʻau lapaʻau i hiki ai i nā mea hana lāʻau paʻa waha ma ʻAmelika ʻAmelika e hoʻokō i ka bioavailability nui ma o ka hoʻohana ʻana i nā kahua hoʻopuka lāʻau hou. Manaʻo ʻia kēia e hoʻokau i ka noi no ka hoʻokuʻu ʻana i ka ʻenehana lawe lāʻau lapaʻau i ka ʻāina.
Kaomi no ka loaʻa ʻana o ka laʻana: https://www.futuremarketinsights.com/reports/sample/rep-gb-4400
Eia nō naʻe, ʻo ka hoʻonui ʻana i nā hana noiʻi e pili ana i nā molekala biologic, a me ko lākou mana i ka mālama ʻana i nā kūlana oncology, i hui pū ʻia me nā hoʻopukapuka aupuni i kēia mau hana noiʻi e manaʻo ʻia e pale i ka ulu ʻana o ka mākeke ma ʻAmelika ʻAmelika. Eia kekahi, ʻo nā pilikia hoʻohālikelike e like me ka juncture o nā manaʻolana o ka mākeke no ka dosing hoʻokahi i kēlā me kēia lā, a me ka ulu ʻana o nā papa hoʻokuʻu hoʻokuʻu ʻia e hāʻawi ana i ka hoʻomāinoino ʻana, i loaʻa i ka ʻenehana lawe lāʻau hoʻokuʻu waha e manaʻo ʻia e hoʻonui i ka ulu ʻana o ka mākeke ma kēia wahi.
ʻO nā mea kemika hou e loaʻa mai ana mai ke kiʻekiʻe throughput screening e alakaʻi i ka ulu ʻana o ka mākeke ma ʻEulopa Komohana
E hoʻopaʻa inoa ʻo Western Europe i ka hoʻonui wikiwiki ʻana i ka mākeke oral controlled release drug delivery market. Kuhi ʻia kēia ulu ʻana i ka luku ʻana o nā mea kemika hou i loaʻa mai ka nānā ʻana i ka throughput kiʻekiʻe, he haʻahaʻa haʻahaʻa a me ka bioavailability. Ua alakaʻi hou kēia i nā mea hana ma kēia wahi e hoʻopukapuka i nā ʻano lawe lāʻau lapaʻau me ka hopena lapaʻau ʻoi aku ka maikaʻi. Ma muli o ke kumu kūʻai ma nā ʻāina ʻEulopa Komohana, ʻo nā ʻenehana e hoʻonui ai i ka bioavailability e hoʻomau i ka ʻōnaehana lawe lāʻau. Kuhi ʻia kēia mau mea e alakaʻi i ka ulu ʻana o ka mākeke ma kēia wahi.
Eia nō naʻe, ʻo ka hapa nui o nā hui lāʻau lapaʻau ma ʻEulopa Komohana he kaulahao lako paʻakikī, ʻaʻole i hoʻohana ʻia a ʻaʻole pono. Hoʻopili ʻia ka paʻakikī o ke kaulahao hoʻolako i ka haʻahaʻa haʻahaʻa a me ke kumu kūʻai. Eia kekahi, ʻo ka hoʻopōkole ʻana i ke ola patent kūpono me nā pali patent he mea paʻakikī nui ia no nā ʻano lāʻau paʻa waha ma kēia ʻāina. Kuhi ʻia nā mea e like me kēia e pale i ka ulu ʻana o ka mākeke ma Western Europe.
Dissolution-Controlled Release System e hoʻomau i ka ʻimi ʻia ma waena o nā ʻenehana hoʻokuʻu lāʻau i ka mākeke
Ma o ka ʻenehana hoʻokuʻu lāʻau, e ʻimi mau ʻia ka ʻōnaehana hoʻokuʻu dissolution-controlled ma ka mākeke, a ukali ʻia e ka diffusion-controlled system release. Loaʻa ka hapa nui o nā formulations generic i loko o ke ʻano ʻano ʻano papa a hahai i ka mīkini hoʻokuʻu i hoʻokuʻu ʻia. ʻO nā loaʻa mai ke kūʻai aku ʻana i ka ʻōnaehana hoʻokuʻu i hoʻokuʻu ʻia e ka dissolution e ʻoi aku ma mua o US $ 10,000 Mn ma 2017. ʻO ka noi no ka ʻōnaehana hāʻawi lāʻau hydrodynamically-balanced e noho lohi i ka mākeke.
Manaʻo ʻia nā ʻano dosage paʻa o ka hoʻokuʻu waha ʻana i ka ʻenehana lawe lāʻau e hoʻomau i ka mana ma ka mākeke, e hoʻonui ana i kahi CAGR kiʻekiʻe hoʻokahi-helu a hiki i 2027. E hoʻopaʻa inoa ka kūʻai ʻana o ka semisolid / wai / suspensions dosage form i kahi CAGR haʻahaʻa haʻahaʻa ma mua o ka paʻa. nā ʻano dosage i ka mākeke a hiki i 2027.
ʻO nā mea pāʻani mākeke koʻikoʻi i ʻike ʻia ma ka hōʻike a FMI ʻo AstraZeneca Plc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Industries Ltd, Abbott Laboratories, Merck & Co. Inc., Novartis AG, Pfizer Inc., Mylan NV, Sanofi, F. Hoffman-La -Roche Ltd., Johnson & Johnson Services, Inc., Vectura Group plc., GlaxoSmithKline plc.
Kaomi e kiʻi i ka TOC hohonu o kēia Hōʻike: https://www.futuremarketinsights.com/reports/oral-controlled-release-drug-delivery-technology-market/table-of-content
E pili ana i ka Māhele mālama ola ma Future Market Insights
Mālama ʻo Future Market Insights i nā ʻoihana, aupuni, nā mea hoʻopukapuka, a me nā mea e pili ana i ka ʻoihana mālama olakino e ʻike a hoʻokūkī i nā mea koʻikoʻi e pili ana i ka hoʻolālā huahana, ka ʻāina hoʻoponopono, ka hoʻomohala ʻenehana, a me nā pilikia koʻikoʻi e hoʻokō ai i ka kūleʻa mau. ʻO kā mākou ala kūʻokoʻa i ka hōʻiliʻili ʻana i ka ʻike mākeke e hoʻolako iā ʻoe i ka hoʻolālā ʻana i nā alahele i hoʻoikaika ʻia no kāu ʻoihana. E ʻike hou aku e pili ana i kā mākou ʻāpana ʻāpana ma aneʻi
About Ka Makahiki Hou (FMI)
ʻO Future Market Insights (FMI) kahi alakaʻi alakaʻi o ka mākeke naʻauao a me nā lawelawe kūkākūkā, e lawelawe ana i nā mea kūʻai aku ma luna o 150 mau ʻāina. Aia ʻo FMI i ke keʻena nui ma Dubai, a loaʻa iā ia nā kikowaena lawe ma UK, US a me India. ʻO nā hōʻike noiʻi mākeke hou a FMI a me ka nānā ʻana i nā ʻoihana e kōkua i nā ʻoihana e hoʻokele i nā pilikia a hana i nā hoʻoholo koʻikoʻi me ka hilinaʻi a me ka maopopo ma waena o ka hoʻokūkū breakneck. Hāʻawi kā mākou hōʻike noiʻi mākeke maʻamau a syndicated i nā ʻike hiki ke alakaʻi i ka ulu hoʻomau. Hoʻomau mau ka hui o nā mea loiloi alakaʻi akamai ma FMI i nā ʻano e kū mai ana a me nā hanana i loko o kahi ākea o nā ʻoihana e hōʻoia i kā mākou mea kūʻai aku e mākaukau no nā pono e ulu nei o kā lākou mea kūʻai.
Kāhea iā mā˚ou:
Nā Hōʻikeʻike o ka Makahiki Hou
Mokuna No: AU-01-H ʻO ka Hale Hōʻikeʻike gula (AU), No Kūkulu: JLT-PH1-I3A,
ʻO Jumeirah Lakes Towers, Dubai,
United Arab Emirates
No nā Nīnau Nīnau: [pale ʻia ka leka uila]
No nā nīnau Media: [pale ʻia ka leka uila]
Paena pūnaewele: https://www.futuremarketinsights.com
He aha e lawe ʻia mai kēia ʻatikala:
- Eia kekahi, ʻo nā luʻina hoʻohālikelike e like me ka juncture o nā manaʻolana o ka mākeke no ka dosing hoʻokahi i kēlā me kēia lā, a me ka ulu ʻana o nā papa hoʻokuʻu hoʻokuʻu ʻia e hāʻawi ana i ka hoʻomāinoino ʻana, i loaʻa i ka ʻenehana hoʻopuka lāʻau hoʻokuʻu waha e manaʻo ʻia e pale hou i ka ulu ʻana o ka mākeke ma kēia wahi.
- Manaʻo ʻia nā ʻano dosage paʻa o ka hoʻokuʻu ʻia ʻana o ka lāʻau lapaʻau i ka mākeke, e hoʻonui ana i kahi CAGR kiʻekiʻe hoʻokahi a hiki i 2027.
- Eia nō naʻe, ʻo ka hoʻonui ʻana i nā hana noiʻi e pili ana i nā molekala biologic, a me ko lākou mana i ka mālama ʻana i nā kūlana oncology, i hui pū ʻia me nā hoʻopukapuka aupuni i kēia mau hana noiʻi e manaʻo ʻia e pale i ka ulu ʻana o ka mākeke ma ʻAmelika ʻAmelika.
